Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Tuned out

Controlling kinase inhibitors’ residence time via reversible covalent binding is of high interest in drug discovery. Tuning reversible covalent binding kinetics using a pan-kinase inhibitor that reacts with the catalytic lysine enabled exquisite temporal selectivity in vitro and in vivo.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Reversible covalent targeting of catalytic lysines enables residence-time-based selectivity across the kinome.


  1. Liu, Q. et al. Chem. Biol. 20, 146–159 (2013).

    Article  Google Scholar 

  2. Yang, T. Nat. Chem. Biol. (2022).

    Article  PubMed  Google Scholar 

  3. Dungo, R. T. & Keating, G. M. Drugs 73, 1503–1515 (2013).

    CAS  Article  Google Scholar 

  4. Dangi-Garimella, S. Am. J. Manag. Care 20, E10 (2014).

    PubMed  Google Scholar 

  5. Serafimova, I. M. et al. Nat. Chem. Biol. 8, 471–476 (2012).

    CAS  Article  Google Scholar 

  6. Chaikuad, A., Koch, P., Laufer, S. A. & Knapp, S. Angew. Chem. Int. Ed. Engl. 57, 4372–4385 (2018).

    CAS  Article  Google Scholar 

  7. Abbasov, M. E. et al. Nat. Chem. 13, 1081–1092 (2021).

    CAS  Article  Google Scholar 

  8. Vichinsky, E. et al. N. Engl. J. Med. 381, 509–519 (2019).

    CAS  Article  Google Scholar 

  9. Eid, S., Turk, S., Volkamer, A., Rippmann, F. & Fulle, S. BMC Bioinformatics 18, 16 (2017).

    Article  Google Scholar 

  10. Zhao, Q. et al. J. Am. Chem. Soc. 139, 680–685 (2017).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Fleur M. Ferguson.

Ethics declarations

Competing interests

F.F. is a scientific co-founder and equity holder in Proximity Therapeutics, and a scientific advisory board member and equity holder in Triana Biomedicines. F.F. is or was recently a consultant or received speaking honoraria from RA Capital, Tocris BioTechne and Plexium Inc. The Ferguson lab receives or has received research funding from Ono Pharmaceutical Co. Ltd.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ferguson, F.M. Tuned out. Nat Chem Biol (2022).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing